Invention Grant
US09011939B2 Sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans for treating diseases caused by the influenza virus
有权
用于治疗由流感病毒引起的疾病的硫酸阿拉伯半乳聚糖，阿维拉半乳糖醛酸和硫酸化杂多糖
- Patent Title: Sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans for treating diseases caused by the influenza virus
- Patent Title (中): 用于治疗由流感病毒引起的疾病的硫酸阿拉伯半乳聚糖，阿维拉半乳糖醛酸和硫酸化杂多糖
-
Application No.: US13977780Application Date: 2012-01-03
-
Publication No.: US09011939B2Publication Date: 2015-04-21
- Inventor: Bruno Lina , Olivier Ferraris , Ho Hong Hai Vo , François-Loïc Cosset , Judit Szecsi , Alain Heyraud , Hugues Lortat-Jacob , Julia Bartoli , Rabia Sadir , Thierry Livache , Benoît Darblade , Stéphane Havet , Silvère Bonnet
- Applicant: Bruno Lina , Olivier Ferraris , Ho Hong Hai Vo , François-Loïc Cosset , Judit Szecsi , Alain Heyraud , Hugues Lortat-Jacob , Julia Bartoli , Rabia Sadir , Thierry Livache , Benoît Darblade , Stéphane Havet , Silvère Bonnet
- Applicant Address: FR Crolles FR Paris FR Paris FR Paris
- Assignee: Elicityl,Centre National de la Recherche Scientifique,Insititut National de la Sante et de la Recherche Medicale—I.N.S.E.R.M.,Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA)
- Current Assignee: Elicityl,Centre National de la Recherche Scientifique,Insititut National de la Sante et de la Recherche Medicale—I.N.S.E.R.M.,Commissariat a l'Energie Atomique et aux Energies Alternatives (CEA)
- Current Assignee Address: FR Crolles FR Paris FR Paris FR Paris
- Agency: Clark & Brody
- Priority: FR1150049 20110104
- International Application: PCT/FR2012/050017 WO 20120103
- International Announcement: WO2012/093234 WO 20120712
- Main IPC: A01N65/00
- IPC: A01N65/00 ; A61K31/737 ; A61K31/715 ; A61K36/05 ; A61K36/888
Abstract:
The present invention relates to polysaccharides selected from sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans intended to be used as a drug for the preventive or curative treatment of an influenza virus, as well as to the pharmaceutical compositions including, in particular in combination with at least one pharmaceutically acceptable carrier: either an extract of Codium fragile, including sulphated arabinogalactans, or an extract of Zostera marina or Lemna minor, including apiogalacturonans, or an extract of Caulerpa racemosa, including sulphated heteroglycans.
Public/Granted literature
Information query
